Catalyst
Slingshot members are tracking this event:
Galmed (GLMD) to Initiate Phase 1/2 Study of Aramchol in Kids with Nonalcoholic Fatty Liver Disease (NAFLD) in H1 2017
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
GLMD |
|
|
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 09, 2018
Occurred Source:
http://galmedpharma.investorroom.com/2018-05-09-Galmed-Pharmaceuticals-Provides-Business-Update-and-Reports-First-Quarter-2018-Financial-Results
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 1/2 Study, Aramchol, Nonalcoholic Fatty Liver Disease, Nafld, Uc-san Diego School Of Medicine, Artisan